4SC AG news, videos and press releases
For more news please use our advanced search feature.
4SC AG - More news...
4SC AG - More news...
- Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
- DGAP-News: 4SC provides Q1 2020 update
- DGAP-News: 4SC AG: Conference call to be hosted on 21 April 2020 to present the Q1 report 2020
- DGAP-News: 4SC AG: FDA Accepts IND Application for MERKLIN 2 Study
- DGAP-News: 4SC AG provides results for financial year 2019 and outlook
- DGAP-News: 4SC to present at the World Congress of Cutaneous Lymphomas in Barcelona, Spain
- DGAP-News: 4SC - Resminostat and RESMAIN Study Update
- DGAP-News: 4SC AG: First Patient Enrolled in DONIMI Study Evaluating Domatinostat in the Neoadjuvant Setting in Melanoma
- DGAP-News: 4SC AG: 3 upcoming conferences
- DGAP-News: 4SC AG enters into avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for clinical combination study of domatinostat in Merkel cell carcinoma
- DGAP-News: 4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
- DGAP-Adhoc: 4SC AG secures circa EUR 22.4 million from a capital increase
- DGAP-News: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma
- DGAP-News: 4SC provides Q3 business update and outlook
- DGAP-News: 4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Domatinostat in the Neoadjuvant Setting in Melanoma
- DGAP-News: 4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Announcement 2019
- DGAP-Adhoc: 4SC AG resolves to issue new shares; Santo and ATS undertake to subscribe / buy the new shares
- DGAP-News: 4SC AG: First domatinostat combination data from Phase Ib/II SENSITIZE study presented at ESMO
- DGAP-News: 4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens
- DGAP-News: 4SC AG: Key resminostat scientific data to be presented at EORTC-CLTF meeting in Athens
- DGAP-News: 4SC AG: Poster presentations at ESMO Congress 2019
- DGAP-News: 4SC AG: 8 upcoming conferences
- DGAP-News: 4SC AG receives milestone payment from Link Health - Link Health initiates Phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma
- DGAP-News: 4SC AG provides Q2 and H1 2019 update
- DGAP-News: 4SC AG: Conference call to be hosted on 8 August 2019 to present the half-year report 2019
- DGAP-News: 4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
- DGAP-News: 4SC AG: Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma
- DGAP-Adhoc: 4SC AG secures EUR 11 million from capital increase
- DGAP-Adhoc: 4SC AG announces subscription price for new shares from current capital increase
- DGAP-Adhoc: 4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat and domatinostat
